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Abstract The aim of the present study was to monitor
photodynamic angioocclusion with verteporfin in capillar-
ies. Details of this process were recorded under a microscope
in real-time using a high-sensitivity video camera. A pro-
cedure was developed based on intravenous (i.v.) injection of
a light-activated drug, Visudyne, into the chorioallantoic
membrane (CAM) of a 12-day-old chicken embryo. The
effect of light activation was probed after 24 h by i.v.
injection of a fluorescent dye (FITC dextran), and analysis of
its fluorescence distribution. The angioocclusive effect was
graded based on the size of the occluded vessels, and these
results were compared with clinical observations. The time-
resolved thrombus formation taking place in a fraction of the
field of view was video recorded using a Peltier-cooled CCD
camera. This vessel occlusion in the CAM model was
reproducible and, in many ways, similar to that observed in
the clinical use of verteporfin. The real-time video recording
permitted the monitoring of platelet aggregation and
revealed size-selective vascular closure as well as some
degree of vasoconstriction. Platelets accumulated at intra-
vascular junctions within seconds after verteporfin light
activation, and capillaries were found to be closed 15 min
later at the applied conditions. Larger-diameter vessels
remained patent. Repetition of these data with a much more
sensitive camera revealed occlusion of the treated area after
5 min with doses of verteporfin and light similar to those
used clinically. Consequently, newly developed light-
activated drugs can now be studied under clinically relevant
conditions.
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Introduction
Subfoveal choroidal neovascularization (CNV) is a
degenerative condition that can cause severe, irreversible
loss of central vision when unidentified and untreated.
CNV can develop secondary to several disorders of the eye,
including age-related macular degeneration (AMD), path-
ologic myopia, and ocular histoplasmosis syndrome [1].
AMD is the leading cause of blindness in people over
50 years of age in the Western world [2].
Thermal laser photocoagulation, as a treatment for CNV
associated with AMD, can induce marked visual loss, and
damage to the retinal pigment epithelium (RPE) and the
neural retina [3]. The angioocclusive mechanism of action
(MoA) of verteporfin (Visudyne, Novartis Pharma AG,
Basel, Switzerland) photodynamic therapy (PDT) repre-
sents one treatment option. The efficacy of verteporfin PDT
has been investigated in more than 1,000 patients in Phase
III trials. The first of these were the ‘Treatment of Age-
related Macular Degeneration with Photodynamic Ther-
apy’ (TAP) and Phase IIIb ‘Verteporfin in Photodynamic
Therapy’ (VIP) studies [4, 5]. The benefits of verteporfin
therapy on visual acuity were evident as early as 3 months
after initial treatment, and were sustained throughout the
1- to 2-year follow-up periods, and eventually up to 6 years
[4–7]. Verteporfin PDT is a minimally invasive, two-step
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process based on the interaction of verteporfin—an intra-
venously administered, non-toxic light-activated drug—
with molecular oxygen. This interaction occurs after light
is applied at an appropriate wavelength to the CNV lesion
in the macula, where the verteporfin has accumulated to
some extent preferentially [8], using a non-thermal diode
laser device. The initial reaction of the light-activated drug
with molecular oxygen leads to, among others, a short-
lived reactive singlet oxygen intermediate, which reacts
with the surrounding biomolecules and activates a cascade
of chemical and physiological responses in the endothelial
cells, which result in occlusion of the treated neovascu-
larization [9]. Verteporfin (also known as benzoporphyrin-
derivative monoacid ring A [BPD-MA]) is the active
chemical component of the liposomal verteporfin formu-
lation (Visudyne), and is a potent, second-generation,
light-activated drug derived from hematoporphyrin [10].
Animal studies have shown that the liposomal formulation
of verteporfin accumulates selectively in the neovascula-
ture by forming complexes with low-density lipoproteins
(LDLs) [11, 12]. A clinical pharmacokinetic study further
demonstrated that the retinal vessels are drained faster than
the choroidal vessels, thus providing a time window of
selectivity that helps, at least to some extent, to preserve
the precious retinal capillaries [13–16]. The latter are
probably also protected to some extent by the blood–retinal
barrier. Most photosensitizers used in PDT induce vascular
effects during and/or after light exposure of the tissue
containing the photosensitizer. The mechanisms by which
PDT induces haemostasis have been investigated in some
detail. The main target of vascular PDT appears to be the
endothelial cell [17–19]. The injected photosensitizer
arrives at the endothelial cells and is partially internalized.
Measuring the intracellular distribution of photosensitizing
porphyrins has shown that, depending on the physico-
chemical properties of the porphyrin, its fluorescence can
be localized in the plasma membrane, cytoplasm, nuclear
membrane, and nucleoli [20]. Light application causes the
above-mentioned oxygen-radical-mediated damage to the
cytoskeleton and other targets. Thus, PDT causes rounding
and contraction of endothelial cells [9]. This results in the
rupture of interendothelial cell tight junctions, thus
exposing the subendothelial basement membrane (Fig. 1).
PDT induces the release of von Willebrand factor [21],
thromboxane, prostacyclin and other factors, such as vas-
cular endothelial growth factor (VEGF), that result in
increased vascular permeability and exudation, as well as
clotting and vasoconstriction [17, 18, 22]. At the gaps
formed between the rounded endothelial cells, activated
platelets adhere to the damaged vessel wall. Platelets
continue to aggregate and start to plug the vessel, finally
leading to the formation of a fibrin-stabilized thrombus and
vasoconstriction [23]. The ultimate outcome is haemostasis
with tissue hypoxia. Complete occlusion of the choroidal
neovasculature can occur within 1 day. PDT can close
smaller vessels more easily than larger vessels, as has been
observed in the human choroid. Generally, the diameter of
a vessel that can be occluded depends on the amount and
location of the photosensitizer and on the light adminis-
tered. Larger-diameter vessels, in which stasis has been
observed, may re-open so that perfusion can be re-
established.
The angioocclusive properties of verteporfin therapy
may close the CNV, sparing to a large extent the overlying
retinal tissues; however, some degree of closure of the
choriocapillaries is also observed [24]. At present, this
unique MoA of verteporfin is still being investigated and,
over the years, there have been considerable efforts to
improve and develop instrumentation for clinical fluo-
rescence diagnosis and PDT. Recent advances in under-
standing the multi-component pathogenesis of AMD, and
the role of VEGF in CNV progression, have led to the
development of antiangiogenic therapies. The latter include
injection of the anti-VEGF agent ranibizumab (Lucentis)
[25]. Intravitreal ranibizumab had clinically been shown to
safely prevent vision loss. It also improved mean visual
acuity, over a 2-year period, in patients with minimally
classic or occult CNV due to AMD [26]. Due to the promise
of combining verteporfin with anti-VEGF and/or anti-
inflammatory therapies, there is great interest in discovering
and developing increasingly more selective photosensitizers
to be used in the treatment of CNV due to AMD. Conse-
quently, efficient in vivo drug screening procedures that
help define vascular PDT effects are vital in the develop-
ment of new photosensitive drugs and optimizing the
experimental conditions. An extensive intercomparison of
photosensitizers for PDT closure of CNV associated with
AMD has been initiated using an in vivo model optimized
for vascular thrombosis studies [27].
The chorioallantoic membrane (CAM) of the chicken
embryo has been used as an in vivo assay for PDT and as a
model for studying biological processes related to high
angiogenic activity. In this model, the vessels are of the
neovessel type and are representative of neovascular
growth due to the embryonic phase of the egg; thus, the
events occurring at the cellular level can be, at least to
some extent, linked to those occurring at the endothelial
cell level of the CNV neovessels in the eye. This approach
allows for concurrent observation of the activity of dif-
ferent photosensitizers, as well as direct visualization of
blood vessels before, during, and after PDT. The CAM is a
major respiratory organ of the chicken embryo, and the
well-vascularized surface is formed through fusion of two
mesodermal layers. It is relatively inexpensive, easily
accessible, and has a high transparency that allows nearly
any wavelength in the visible and near infrared parts of the
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electromagnetic spectrum to be used in dye excitation and
fluorescence analyses, making it ideal as a model for
directly observing the vascular effects of PDT.
The aim of this study was to monitor the mechanisms of
angioocclusion with verteporfin PDT at the capillary ves-
sels level and to record events in real-time, using a high-
sensitivity video camera.
Methods
An experimental procedure was developed using intrave-
nous (i.v.) injection of various photosensitizers and fluo-
rescent dyes into the CAM for drug screening and prediction
of clinical features.
CAM preparation
Fertilized chicken eggs were disinfected, numbered, and
transferred into a turning incubator, set at 37C and 60%
humidity [27]. On embryo development day (EDD) 3, a
hole of approximately 3 mm in diameter was drilled into
each eggshell and covered with cling film. The eggs were
then returned to the incubator in a static position until use
at approximately EDD 12 [27]. The correlation in PDT
vessel closure efficiency between the model and CNV in
human eyes was established using both verteporfin and
lutetium texaphyrin (Lutex), because data were available
on both substances from both CAM and human clinical
trials. The angiographic dyes indocyanine green and fluo-
rescein were also tested in both model and clinical context.
Measuring angioocclusion
On EDD 13, the holes were extended to a diameter of
approximately 30 mm, and the embryos were placed under
an epi-fluorescence microscope (Nikon Eclipse E600 FN,
Japan) equipped with long-working-distance Nikon objec-
tives (CFI 49/0.10, WD = 30; PlanFluor 109/0.30,
WD = 16; L-Plan SLWD 209/0.35, WD = 24; or L-Plan
SLWD 509/0.45, WD = 17) and with an F-view II 12-bit
monochrome Peltier-cooled digital CCD camera driven
with analySIS docu software from Soft Imaging System
(Mu¨nster, Germany).
Verteporfin was intravenously injected into the vascu-
lature of the fertilized chicken eggs. The development of
thrombosis was recorded during and after light activation
in real-time using the described digital CCD camera or an
ultra-high-sensitivity video camera (EM-CCD, Hamama-
tsu, Japan) (Fig. 2). This on-chip amplified Hamamatsu
electron multiplier, back-thinned, Peltier-cooled CCD
camera (EM-CCD C9100-12; 400–1,000 nm) provided up
to 2,0009 signal amplifier gain, thus allowing a lower level
of excitation light to be used. This level of excitation
corresponds closely to that used in the human eye. Images
and sequences were recorded through the Hamamatsu
Fig. 1 A simplified sequence describing verteporfin PDT-induced
changes to the endothelium. (a) Blood vessel wall before verteporfin
PDT; endothelial cells lining the vessel wall are bound by tight
junctions. (b) Verteporfin PDT-induced oxidative stress to the endo-
thelium alters the cytoskeleton and triggers rounding and retraction of
endothelial cells, consequently exposing subendothelial connective
tissue; von Willebrand (von-WF) and other clotting factors are released
at the exposed site, and platelets adhere to the damaged surface. (c)
Finally, a stabilized fibrin plug is formed as the blood clots
Fig. 2 Experimental set-up. Excitation was performed at 420 nm for
verteporfin activation and 470 nm for FTIC fluorescence recording
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camera controller with the Hamamatsu HiPic version 7.0
software, giving 512 9 512 pixels, 16-bit grey-level ima-
ges. Selective angioocclusion, as controlled mainly by the
optical field of exposure (diaphragm), was observed in the
CAM chicken embryo model, following verteporfin ther-
apy. This was done by visualizing the location and
aggregation of platelets on video recordings. Images were
recorded at 12 frames per second.
Results
Standard-sensitivity camera
Vessel occlusion, similar to that in clinical PDT, was
reproducible in the CAM model. Total photothrombosis of
treated vessels was observed at a photosensitizer dose of
0.15 mg/kg and 60 J/cm2 of 689 nm light in the human eye,
and 0.4 mg/kg photosensitizer and 25 J/cm2 at 420 nm in the
CAM model (Fig. 3). Standard doses in humans are 6 mg/m2
body surface area, approximately 0.15 mg/kg body weight,
and 50 J/cm2 of 689 nm light applied for 83 s at an intensity
of 600 mW/cm2, 15 min after the start of injection, which
lasted for *10 min. Standard doses for the CAM were
0.2 mg/kg body weight of embryo (*10 g) [28], and
20 J/cm2 of a filtered Hg-arc lamp at 420 ± 20 nm light for a
duration of *60 s at a fluence of 330 mW/cm2. This tech-
nique allowed a real-time view of verteporfin-induced
angioocclusive events in the CAM of a gestating chicken
egg.
The video recording permitted monitoring of the loca-
tion and speed of adhesion, aggregation and release of
platelets, and showed an end result of selective vascular
closure (Fig. 4). Platelets built up at intracellular junctions
seconds after the activation of verteporfin. Formation of a
stabilized plug leading to complete closure of a capillary
was observed 15 min after verteporfin activation, while
bloodflow continued in the much larger-diameter main
vessel (Fig. 4). Because a relatively high magnification
(509) was used to optimize the observation of angiooc-
clusion at the capillary vessels level, the observed area
received a higher fluence rate (C1 W/cm2) compared with
the clinical situation (600 mW/cm2).
Ultra-high-sensitivity camera
With this magnification (509), to record angioocclusion
under conditions that were close to the clinical setting, the
excitation light had to be lowered by two orders of magni-
tude to maintain a fluence level much lower than 330 mW/
cm2 on the CAM surface, and thus did not cause PDT while
recording video images. Therefore, the sensitivity of the
recording device (EM-CCD) was increased proportionately
to record images at the lower illumination. The ultra-high-
sensitivity camera permitted monitoring of angioocclusion
using verteporfin PDT with light and drug doses similar to
those utilized in the human clinical setting (Fig. 5). Fol-
lowing a co-injection of verteporfin and FITC dextran, light
was applied to the treated area for 1 min at a wavelength of
420 nm, followed by administration of a non-therapeutic
wavelength (470 nm) (verteporfin absorbance 1/3) attenu-
ated to 1/30 (*10 mW/cm2) to record the flow of blood
within the vessels (FITC dextran fluorescence), using two
different magnifications (Nikon 109, 509) (Fig. 5). Thus,
the resultant excitation was reduced to *1% of the original
excitation. Occlusion of the treated area was observed after
5 min of light exposure at a wavelength of 420 nm (Fig. 5b–f
for 109, and Fig. 5g–j for 509 magnification).
The effect of light dose and drug concentration on the
level of angioocclusion with verteporfin was also investi-
gated in the CAM model, using a 6-point scale from 0 (no
occlusion) to 5 (total occlusion in treated area) (Table 1).
Twenty-four hours after treatment, a dose-proportional
increase in the level of vascular occlusion was observed
with increasing fluence (from 10 to 40 J/cm2) and drug
concentration (from 100 to 200 lg/kg), (Fig. 6a–g).
Discussion
Verteporfin PDT has provided significant improvements in
the management of subfoveal CNV for hundreds of
Fig. 3 Photosensitizer efficacy.
Reproduced with permission
from Ref. [8]
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thousands of patients. The long-term proven stability in
vision often provides additional low-vision rehabilitation
[29, 30], and also a gain in contrast sensitivity, compared
with placebo [31, 32]. PDT has a potential dual selectivity,
because there is a preferential accumulation of verteporfin
in the target tissue, and light application is confined to the
specific target area [24]. Furthermore, the retinal vascula-
ture is protected by the blood–retinal barrier. Selectively
destroying the abnormal new choroidal vessels while
sparing normal vessels in the retina and choroid is crucial
for maintaining neural retina function in CNV therapy. The
selectivity of verteporfin was first demonstrated in animal
models, in which photodynamic damage was spatially
confined to vascular structures [12, 33, 34]. In vivo studies
in the rabbit cornea showed that verteporfin was rapidly
and selectively taken up by neovascular endothelium and
caused a complete and selective occlusion without alter-
ation of the adjacent stroma [35]. Further studies showed
that verteporfin therapy selectively occluded the subretinal
choriocapillary layer while sparing the sensitive overlying
retinal structures [33]. In monkeys, verteporfin selectively
occluded CNV, while sparing retinal vessels and large,
Fig. 4 Images from
illumination of the CAM model
showing formation of a
stabilized plug, leading to
complete closure of the
capillary 15 min after
verteporfin activation. Image
dimensions = 280 9 224 lm
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normal choroidal vessels [15, 36]. Overall, preclinical
studies demonstrated that, although verteporfin therapy
may cause some reversible damage to the RPE and outer
retina, only minimal damage was observed in normal
intraocular tissues such as retinal vessels, underlying cho-
roid, and overlying neurosensory retina [12, 15, 36–38].
These data suggested that verteporfin could be a useful tool
to treat selectively subretinal neovascularization, such as
CNV in AMD. The aim of verteporfin therapy is to
selectively occlude or destroy CNV, while sparing perfu-
sion in the deeper, larger choroidal vessels and overlying
retinal tissue and retinal vessels. A dose-ranging study
showed that the minimally effective and maximally toler-
ated light doses were C25 J/cm2 and significantly less than
150 J/cm2, respectively [39, 40]. At a light dose equal to or
above 150 J/cm2, non-perfusion of neurosensory retinal
vessels was observed leading to blindness spots in those
eyes [40]. The optimal dose was determined to be a 10-min
i.v. infusion of 6 mg/m2 (0.15 mg/kg for a 2 m2, 80 kg
human) verteporfin, and a light dose of 50 J/cm2 delivered
over a period of approximately 83 s. The optimal time for
irradiation (at 690 nm, light intensity 600 mW/cm2) was
15 min after the start of verteporfin infusion. Although
verteporfin therapy is generally considered to be a selective
treatment [24, 41], there is some evidence of choroidal
hypoperfusion following treatment with verteporfin mono-
therapy [42–44].
The CAM chicken embryo is a useful model with which
to investigate Photofrin-based PDT-induced vascular
effects following topical application of a variety of
photosensitizers, including verteporfin, sulfonated chloro-
aluminum phthalocyanine (AlPcSn), and Lutex [45], all
of which were evaluated for their photothrombotic efficacy.
A considerable variation exists between the different
photosensitizers in terms of biophysical and biochemical
characteristics, biodistribution and uptake kinetics, as well
as in terms of the vehicle and/or formulation used [46–50].
Fig. 5 CAM model: (a)
Treated area (disk
area = 0.66 mm) at 109
magnification. (b–f) At 1, 2, 3, 4
and 5 min, respectively, using
109 magnification (Nikon, Plan
Fluor 109/0.30, WD 16 mm;
image size = 1.3 9 1.3 mm).
(g–j) At 1, 2, 3 and 5 min,
respectively, using 509
magnification (Nikon, L Plan
509/0.45, WD 17 mm; image
size = 0.27 9 0.27 mm)
Table 1 Scale of verteporfin PDT-induced angioocclusion in vessels
of the CAM model [27]
Scale of
angioocclusion
efficacy*
Criterion
0 No occlusion
1 Partial closure of capillaries of diameter\10 lm
2 Closure of capillary system, partial closure of
blood vessels of diameter \30 lm and size
reduction of larger blood vessels
3 Closure of vessels of diameter \30 lm and
partial closure of higher order vessels
4 Total closure of vessels of diameter\70 lm and
partial closure of larger vessels
5 Total occlusion of vessels in the treated area
* Intermediate values are found when making the average of different
scores
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The present study reports that real-time video recording of
verteporfin-induced neovessel thrombosis using the CAM
model and a standard-sensitivity camera allowed monitor-
ing of the location, aggregation and release of platelets,
with an end result of selective vascular closure after
5–15 min. Some aspects of the dose-proportionality and
selectivity of verteporfin therapy were demonstrated in the
CAM chicken embryo model. Importantly, the size
Fig. 6 Dose-proportional effect
of increasing light dose and
drug concentration on vascular
occlusion efficacy of verteporfin
in the CAM model
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selectivity of verteporfin for the closure of smaller vessels
was demonstrated in this model—the images show stasis in
the smaller vessels while blood continued to flow in the
larger-diameter vessels. The effects observed after low-
light fluorescence activation of verteporfin showed strong
similarities of the structural effects to those observed in the
human eye during clinical trials. However, there was an
inherent experimental problem, due to the use of a much
higher magnification (509) with this apparatus, which was
needed to observe more closely the events occurring at the
capillary level. Due to the recording of images during the
process of photothrombosis, the area under investigation
received a much higher level of illumination intensity than
in the clinical situation. A more appropriate verteporfin
therapy light level, i.e. close to the clinical context, was
achieved by reducing the illumination intensity and
changing the wavelength to one that was absorbed less,
which together reduced the excitation to *1% of the
previously used levels. In addition, an ultra-high-sensitivity
video camera was used to record the data. The ultra-high-
sensitivity camera permitted monitoring of angioocclusion
under conditions that did not induce more photodynamic
activity while recording images.
The effects of verteporfin therapy on the vasculature are
now being investigated using a nude-mouse dorsal skin-
fold chamber model (at EPFL, CHUV Hospital, Lausanne,
Switzerland). Adult nude mice receive i.v. injections of
verteporfin, and the effects on the vasculature are visual-
ized using intravital microscopy during and after light
activation. The conditions again closely resemble those in
the clinical setting, but because neovessels are not involved
in the present experiments, higher verteporfin doses (94)
and light levels (94) are being used.
With the increasingly widespread use of antiangiogenic
agents, such as ranibizumab, for the treatment of CNV due
to AMD, this model may also provide a useful tool with
which to investigate the potential synergistic effects of
combining angioocclusive verteporfin therapy with anti-
VEGF agents. For example, this model would be useful to
investigate whether anti-VEGF therapies sensitize vessels
to verteporfin PDT or whether the angioocclusive effect
persisted for a longer period of time in the presence of
anti-VEGF agents. Moreover, this model will be instru-
mental in assessing the activity and selectivity of a new
generation of photosensitizers, under a variety of experi-
mental conditions, to be used in the treatment of CNV due
to AMD.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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